1.Campbell KS., Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013. 132:536–44.
Article
2.Benjamin JE., Gill S., Negrin RS. Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol. 2010. 22:130–7.
Article
3.Hazeldine J., Lord JM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev. 2013. 12:1069–78.
Article
4.Huang H., Patel DD., Manton KG. The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci. 2005. 10:192–215.
Article
5.Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000. 356:1795–9.
Article
6.Schleypen JS., Von Geldern M., Weiss EH., Kotzias N., Rohrmann K., Schendel DJ, et al. Renal cell carcinoma-in trating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by speci HLA class I allotypes. Int J Cancer. 2003. 106:905–12.
7.Mandal A., Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther. 2015. 8:47–55.
Article
8.Ruggeri L., Mancusi A., Burchielli E., Aversa F., Martelli MF., Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol. 2007. 19:142–7.
Article
9.Baier C., Fino A., Sanchez C., Farnault L., Rihet P., Kahn-Perles B, et al. Natural killer cells modulation in hematological malignancies. Front Immunol. 2013. 4:459.
Article
10.Viel S., Charrier E., Marcais A., Rouzaire P., Bienvenu J., Karlin L, et al. Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology. 2013. 2:e26011.
Article
11.Miller JS. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program. 2013. 2013:247–53.
Article
12.Rezvani K., Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 2015. 6:578.
Article
13.Lee SB., Cha J., Kim IK., Yoon JC., Lee HJ., Park SW, et al. A high-through put assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun. 2014. 445:584–90.
14.Koo KC., Shim DH., Yang CM., Lee SB., Kim SM., Shin TY, et al. Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS One. 2013. 8:e78049.
Article
15.Cheson BD., Bennett JM., Kopecky KJ., Buchner T., Willman CL., Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003. 21:4642–9.
Article
16.Palumbo A., Rajkumar SV., San Miguel JF., Larocca A., Niesvizky R., Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014. 32:587–600.
Article
17.Cheson BD., Pfstner B., Juweid ME., Gascoyne RD., Specht L., Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007. 25:579–86.
Article
18.Mukaka MM. Statistics corner: a guide to appropriate use of correlation coeffcient in medical research. Malawi Med J. 2012. 24:69–71.
19.Whiteside TL., Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am J Med. 1998. 105:27S–34S.
Article
20.Farnault L., Sanchez C., Baier C., Le Treut T., Costello RT. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol. 2012. 2012:421702.
Article
21.Stringaris K., Sekine T., Khoder A., Alsuliman A., Razzaghi B., Sargeant R, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014. 99:836–47.
Article
22.Parry HM., Stevens T., Oldreive C., Zadran B., McSkeane T., Rudzki Z, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget. 2016. 7:68513–26.
Article
23.Konjevic G., Jurisic V., Banicevic B., Spuzic I. The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol. 1999. 104:144–51.
24.Brenner CD., King S., Przewoznik M., Wolters I., Adam C., Bornkamm GW, et al. Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol. 2010. 40:494–504.
Article
25.Khaznadar Z., Boissel N., Agaugue S., Henry G., Cheok M., Vignon M, et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. J Immunol. 2015. 195:2580–90.
Article
26.Jurisic V., Srdic T., Konjevic G., Markovic O., Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol. 2007. 24:312–7.
Article
27.Mitsiades CS., Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol. 2013. 88(Suppl 1):S5–13.
Article
28.Dunbar EM., Buzzeo MP., Levine JB., Schold JD., Meier-Kriesche HU., Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 2008. 93:1852–8.
Article
29.Jacobs B., Tognarelli S., Poller K., Bader P., Mackensen A., Ullrich E. NK cell subgroups, phenotype, and functions after autologous stem cell transplantation. Front Immunol. 2015. 6:583.
Article